Home › a Stay of Litigation Pending Ipr Does Not Provide a Basis For Extending 30-Stay of Fda Anda Approval
 

Keywords :   


a Stay of Litigation Pending Ipr Does Not Provide a Basis For Extending 30-Stay of Fda Anda Approval

2016-01-14 10:33:58| Biotech - Topix.net

On December 11, 2015, the United States District Court for the Southern District of Indiana granted a motion to stay a Hatch-Waxman litigation pending the outcome of inter partes reviews on two of the patents-in-suit in the litigation. See Eli Lilly and Company, et al. vs. Accord Healthcare Inc., et al. , No.

Tags: of provide stay basis

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05Young face paying mortgage into retirement years
13.05Universal Credit claimants must seek 18 hours work
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
More »